Although the clinical outcomes of cell therapy trials have not met initial expectations, emerging evidence suggests that injury-mediated tissue damage might benefit from the delivery of cells or their secreted products. Pluripotent stem cells (PSCs) are promising cell sources primarily because of their capacity to generate stage- and lineage-specific differentiated derivatives. However, they carry inherent challenges for safe and efficacious clinical translation. This Review describes completed or ongoing trials of PSCs, discusses their potential mechanisms of action, and considers how to address the challenges required for them to become a major therapy, using heart repair as a case study.

尽管细胞疗法试验的临床结果未达到最初的预期，但新兴证据表明，损伤介导的组织损伤可能受益于细胞或其分泌产物的输送。多能干细胞（PSC）是有希望的细胞来源，主要是因为它们具有产生阶段和谱系特异性分化衍生物的能力。但是，它们为安全有效的临床翻译带来了固有的挑战。这篇综述描述了PSC的已完成或正在进行的试验，讨论了它们的潜在作用机制，并考虑了如何以心脏修复为案例研究如何应对使其成为主要疗法的挑战。